Aktis Oncology, Inc.

Aktis Oncology reported progress on its two clinical-stage programs, AKY-1189 and AKY-2519. The company initiated its third Phase 1b clinical trial, BActinium-2, for AKY-2519, expanding its evaluation to lung cancer and other B7-H3 expressing tumors. Aktis also started backfill cohorts in ongoing Phase 1b trials for both AKY-1189 and AKY-2519. Preliminary data for AKY-1189 is anticipated in Q1 2027, and for AKY-2519 in 2027. The company also operationalized its in-house GMP facility, expected to supply clinical trials in the first half of 2027. Financial results for Q3 2026 showed a cash position of $492.9 million, increased collaboration revenue, higher R&D expenses, and a net loss of $29.9 million.

Aktis Oncology, Inc. completed its Initial Public Offering in January 2026, raising approximately $334.4 million in net proceeds. This significantly strengthened the company's financial position, converting a stockholders' deficit into substantial equity. For the six months ended June 30, 2026, the company reported a net loss of $42.5 million on collaboration revenue of $6.6 million, but its liquidity remains strong with $517.3 million in cash and marketable securities.

Aktis Oncology reported Q2 2026 financial results and significant clinical advancements. The company presented positive first-in-human data for AKY-2519, initiated a Phase 1b trial for AKY-2519 in mCRPC, and is enrolling patients in a Phase 1b trial for AKY-1189. Financially, Aktis reported a net loss of $24.1 million, with cash reserves of $517.3 million expected to fund operations into 2029.

Aktis Oncology, Inc. announced that its President and Chief Executive Officer, Matthew Roden, Ph.D., will present at the Jefferies Global Healthcare Conference. The presentation is scheduled for Wednesday, June 3, 2026, at 4:20 p.m. ET, and will be accessible via a live webcast on the company's investor relations website. An archived replay will be available for approximately 90 days following the event. The company will likely discuss its miniprotein radioconjugate platform and clinical-stage pipeline programs, AKY-1189 and AKY-2519.

Aktis Oncology reported positive first-in-human clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting B7-H3 expressing tumors. The data, to be presented at the 2026 ASCO Annual Meeting, demonstrated robust tumor uptake and retention across various solid tumors, including mCRPC, lung, and colorectal cancers, with limited normal tissue exposure. These findings suggest a potentially differentiated therapeutic profile compared to approved radiopharmaceuticals and support the advancement of a broad clinical development program for AKY-2519. The company will host a conference call on May 27, 2026, to discuss the results.

Aktis Oncology reported a net loss of $18.3 million for the three months ended March 31, 2026, an increase from $15.0 million in the prior year. The company successfully completed its initial public offering (IPO) in January 2026, raising approximately $334.4 million in net proceeds. This significant capital infusion dramatically improved the company's financial position, increasing cash and cash equivalents to $371.6 million and resulting in total stockholders' equity of $506.1 million.

Aktis Oncology reported a net loss of $18.3 million for Q1 2026, an increase from $15.0 million in Q1 2025, driven by higher operating expenses. The company's cash, cash equivalents, and marketable securities significantly increased to $538.5 million as of March 31, 2026, primarily due to $365.4 million gross proceeds from its January 2026 IPO, extending its operational runway into 2029. Aktis also advanced its clinical pipeline, initiating a Phase 1b trial for AKY-2519 in mCRPC and continuing enrollment for AKY-1189, with preliminary data for both expected in 2027 and Q1 2027, respectively.

Aktis Oncology reported its first quarter 2026 financial results and provided significant business updates. The company initiated a Phase 1b clinical trial for AKY-2519 in metastatic castration-resistant prostate cancer, with preliminary data expected in 2027, and plans a second Phase 1b basket trial for AKY-2519 in H2 2026. Additionally, AKY-1189 received FDA Fast Track designation for metastatic urothelial cancer, with preliminary Phase 1b data anticipated in Q1 2027. For Q1 2026, Aktis reported a net loss of $18.3 million, an increase from $15.0 million in the prior year, while collaboration revenue grew to $3.2 million. The company maintains a strong cash position of $538.5 million, expected to fund operations into 2029.

Aktis Oncology announced that its President and CEO, Matthew Roden, Ph.D., will present at the BofA Securities Health Care Conference on May 13, 2026. The presentation will be webcast live and an archived replay will be available for 90 days. Aktis Oncology is a clinical-stage company developing targeted radiopharmaceuticals, with lead programs AKY-1189 and AKY-2519 in its pipeline, and a collaboration with Eli Lilly and Company.

Aktis Oncology, Inc. announced the initiation of a Phase 1b clinical trial for AKY-2519, a B7-H3 targeted radiopharmaceutical, in patients with metastatic castration-resistant prostate cancer (mCRPC). This is part of a two-trial development strategy, which includes a second Phase 1b basket trial for other B7-H3 expressing solid tumors planned for the second half of 2026. Preliminary data from the mCRPC trial are expected in 2027, aiming to evaluate AKY-2519 broadly and efficiently generate indication-relevant data.